Intervention Protocol

3,4-Diaminopyridine for myasthenia gravis

  1. Charlotte Vrinten1,*,
  2. Stephanie S. Weinreich1,
  3. Rob JPM Scholten2,
  4. Jan JGM Verschuuren3

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 15 FEB 2012

DOI: 10.1002/14651858.CD009675

How to Cite

Vrinten C, Weinreich SS, Scholten RJPM, Verschuuren JJGM. 3,4-Diaminopyridine for myasthenia gravis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD009675. DOI: 10.1002/14651858.CD009675.

Author Information

  1. 1

    VU University Medical Center, Community Genetics Section, Clinical Genetics, 1007 MB Amsterdam, Netherlands

  2. 2

    Academic Medical Center, Dutch Cochrane Centre, Amsterdam, Netherlands

  3. 3

    Leiden University Medical Center, Department of Neurology, Leiden, Netherlands

*Charlotte Vrinten, Community Genetics Section, Clinical Genetics, VU University Medical Center, BS7, D420, PO Box 7057, 1007 MB Amsterdam, Netherlands.

Publication History

  1. Publication Status: New
  2. Published Online: 15 FEB 2012




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of 3,4-DAP for autoimmune MG, transient NMG and the CMS on 1) endurance, and 2) muscle strength, quality of life and Myasthenia Gravis Foundation of America (MGFA) status.